Tandem Diabetes Care is developing several new insulin pumps to offer patients choices, starting with the Mobi miniaturized one, which was recently approved by the FDA, CEO John Sheridan explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview on Tandem’s product pipeline, the upcoming launch of Mobi, including the temporary disruption in 2H as patients wait for the product, and the importance of a mentor to build the right culture.
See omnystudio.com/listener for privacy information.
Vanguards of Health Care by Bloomberg Intelligence